At the annual meeting of the National Comprehensive Cancer Network (NCCN), experts discuss updates and key issues for select NCCN Guidelines, new and emerging therapies, and more, along with special sessions of interest to the care team, such as barriers to care and practice.
CDK4/6 Inhibitors, SERDs, and More in NCCN Talk on Breast Cancer Updates
April 1st 2022NCCN guidelines are no longer “a group of monotherapy choices,” but selections that feature partners for endocrine therapy, highlighted William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Read More
Cancer Care Closer to Home—or at Home—Is Worth Extra Effort, NCCN Panelists Say
April 1st 2022From taking part in clinical research at a local location to foregoing aggressive therapy in favor of quality of life, patients with cancer are seeking new options, said panelists at the 2022 Annual Conference of the National Comprehensive Cancer Network (NCCN).
Read More
NCCN Panel Discusses Challenges, Potential Solutions for Racial Disparities in Cancer Care
March 20th 2021A keynote session at the NCCN Virtual Annual Conference brought a panel of patient advocates and experts together for a timely and necessary discussion about strategies to reduce racial disparities in oncology.
Read More
Benefits and Challenges of ePRO Implementation in Oncology
March 19th 2021During a session at the National Comprehensive Cancer Network (NCCN) annual virtual conference, the payer perspective and physician experiences with PRO systems in both the community and academic medical center settings took center stage.
Read More
Cancer Survivors Returning to Work: Barriers and Interventions
March 18th 2021Amye J. Tevaarwerk, MD, director of the Survivorship Program at the University of Wisconsin Carbone Cancer Center, discussed the impact that cancer diagnosis and treatment can have on survivors when it comes to work.
Read More
Dr Toby Campbell Outlines the Importance of Early End-of-Life Care Discussions
March 25th 2019The move to value-based care has increased the use of palliative care, and new research has found that conversations about end-of-life care should be happening earlier, said Toby C. Campbell, MD, MSCI, of the University of Wisconsin Carbone Cancer Center.
Read More
NCCN Ovarian Cancer Guidelines Add Options for PARP Inhibitors, Bevacizumab
March 25th 2019A presentation Saturday at the National Comprehensive Cancer Network Annual Conference in Orlando, Florida, outlined several key updates for treatment in ovarian cancer based on new studies and approvals for poly (ADP-ribose) polymerase (PARP) inhibitors and bevacizumab.
Read More
Dr David M. O'Malley on Identifying Which Patients Will Respond to PARP Inhibitors
March 24th 2019We're getting better at identifying which patients with ovarian cancer will respond to poly ADP-ribose polymerase (PARP) inhibitors, but we have a long way to go, said David M. O'Malley, MD, professor of medicine, Department of Gynecology, and director of Gynecologic Oncology Clinical Research at the James Cancer Center, Ohio State University.
Read More
Dr Gary Lyman Sees Knowledge of Biosimilars in Cancer Has Improved
March 24th 2019Although there is still a need for more education around the use of biosimilars in cancer, it seems oncologists have become more knowledgeable in the past few years, said Gary H. Lyman, MD, MPH, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance.
Read More
The Art and Science of Talking About End-of-Life Care
March 24th 2019On the last day of the 2019 National Comprehensive Cancer Network Annual Conference, a thoracic oncologist and palliative care physician shared strategies and specific phrases for guiding end-of-life discussions that have been developed, tested, and studied at the University of Wisconsin.
Read More
Aging Population, Rising Morbidity Add to Challenge of Survivorship
March 23rd 2019As more cancer survivors live longer, the challenges increase for those responsible for coordinating care among primary care providers, specialists, and oncologists. The concept of survivorship continues to evolve to include life long after cancer treatment, according to updated guidelines from the National Comprehensive Cancer Network.
Read More
Dr John Ward on Conversations With Patients After Multigene Testing
March 22nd 2019Multigene testing provides a lot of information that providers have to be familiar with in order to adequately explain it to their patients, said John H. Ward, MD, Huntsman Cancer Institute at the University of Utah.
Read More
Dr John Sweetenham Discusses the Impact of CMS' Proposal on Access to CAR T-Cell Therapies
March 22nd 2019CMS’ proposal that patients be enrolled in a clinical trial or registry to get Medicare coverage for chimeric antigen receptor (CAR) T-cell therapies will help improve access, for the most part, but there is the risk that some organizations will choose not to offer this treatment, said John W. Sweetenham, MD, of Huntsman Cancer Institute at the University of Utah.
Read More
NCCN Panel Digs Into Reality of CAR T-Cell Reimbursement
March 21st 2019A panel during the opening day of the 2019 National Comprehensive Cancer Network Annual Conference examined the recent process for National Coverage Determination for chimeric antigen receptor (CAR) T-cell therapy and what it means for the future of innovative treatments.
Read More
Oncologist Shares Lessons Learned From CAR T-Cell Therapy in ALL
March 27th 2018On the closing day of the National Comprehensive Cancer Network (NCCN) 23rd Annual Conference in Orlando, Florida, Bijal Shah, MD, of Moffitt Cancer Center, presented on acute lymphoblastic leukemia (ALL), and on the lessons learned from the application of chimeric antigen receptor (CAR) T-cell therapy in this indication.
Read More
Oncologists Must Weigh Risks, Benefits of Immune Checkpoint Inhibitors
March 26th 2018The use of immune checkpoint inhibitors has revolutionized the treatment of cancer, said John A. Thompson, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, but “With this good news has come some not so good news”: immune-related adverse events can cause serious harm to patients receiving these drugs.
Read More
Clinicians Discuss New Directions in the Treatment of Breast Cancer
March 24th 2018At the National Comprehensive Cancer Network (NCCN) 23rd Annual Conference, held March 22-24 in Orlando, Florida, Sharon H. Giordano, MD, MPH, the University of Texas MD Anderson Cancer Center; Anthony D. Elias, MD, University of Colorado Cancer Center; and William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, provided an update on the NCCN guidelines for the treatment of breast cancer and discussed new directions in breast cancer therapy.
Read More
Roundtable Finds Little Consensus on How to Define "Value" in Value-Based Care
March 24th 2018During a Friday session of the National Comprehensive Cancer Network 23rd Annual Conference in Orlando, Florida, Cliff Goodman, PhD, of the Lewin Group, moderated a multi-stakeholder panel discussion on delivering and receiving cancer care in value-based care models.
Read More